Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Merck, a leading science and technology company, and Siemens deepened their cooperation aimed at taking smart manufacturing ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155 ...

(MRK) said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda in combination with pemetrexed and platinum chemotherapy as a first-line treatment for ...

Under a MOU signed between both the parties, Merck and Siemens have decided to expand their cooperation in Smartfacturing.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In a report released on September 11, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – ...

Yes. I think it depends on the therapeutic area. So if I look at where we are today, the two products we just talked about are very different. So if I think through KEYTRUDA, roughly around 60% of my ...